MRVI

Maravai LifeSciences Holdings

MRVI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,443

Bullish sentiment (50-day avg)96%

Price to earnings ratio28.4

Market capitalization2.8B

Earnings per share-0.53

Dividend yield (TTM)—

Revenue (annual)185.7M

Net income (annual)-230.8M

Social

What share of all stock conversation is about MRVI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 20

Maravai LifeSciences Holdings, Inc. (MRVI) jumped 14% to $8.24, extending a 26% pop the day before, after Moderna-Merck news.
MRVI's product, nucleic acids and mRNA building blocks, are essential for drug makers to build therapies, making it a key player in the industry.
MRVI is also being considered as a potential sleeper in the space, with its CDXs possibly holding value.

Generated by AI

Sentiment

Of the messages about MRVI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	75% -21.41	87.79% +14.9
Bearish	—	—	25% +21.41	12.21% -14.9

Bullish· Feb 23

$MRVI is expected to reach $10-12 next week, with buying activity ahead of the next week's ramp up.
$MRVI is forming a base, setting up for a potential move, with some investors already taking positions at current levels.
$MRVI's recent earnings beat and revenue topping estimates are seen as a positive sign for the company's future, with some investors expecting the stock to reach $14+.

Bearish· Feb 25

$MRVI has experienced a significant decline in value, with some analysts downgrading it to "Sell" and others giving it a "Hold" rating with negative signals and a falling trend.
Maravai Lifesciences is under investigation for securities fraud, which has led to a 24% decline in the stock's value and a $13.74M "smart money" net outflow.
The company's poor performance has led to a loss of investor confidence, with many investors experiencing significant losses and some even averaging down their positions in anticipation of a future buyout.

Generated by AI

Topics

Of the messages about MRVI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	42.5%	63.05%
Technical Analysis	100%	100%	57.5%	10.25%
Analysts	0%	0%	0%	9.77%
Earnings	0%	0%	0%	8.82%
Macro	0%	0%	0%	8.1%
Controversies	0%	0%	0%	0%

Announcements· Sep 7

Maravai LifeSciences Holdings, Inc. ($MRVI) has launched a proposed secondary offering of Class A common stock by selling stockholders.
The company announced that Thompson Street Capital Partners has acquired Vector Laboratories, a protein detection business.
Maravai LifeSciences Holdings, Inc. has filed a Form S-1 registration statement with the SEC, indicating plans for a potential IPO.

Technical Analysis· Jul 23

A golden cross is forming on the daily chart, indicating a bullish structure, and traders are advised to trade pullbacks to the 50 SMA.
The price is forming higher lows, creating an ascending triangle pattern, and a measured breakout could aim toward the $8.00 region.
The price is testing horizontal resistance, and a breakout on above-average volume could confirm bulls and target the next swing high, but failure to breach with volume may lead to a short-term pullback to support.

Generated by AI

Community

Of the messages about MRVI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	27.63%	26.25%
Newcomers	100%	100%	72.37%	73.75%

Regulars· Aug 8

Maravai LifeSciences Holdings, Inc. (MRVI) is experiencing a significant decline in the pre-market, down -11.16%.
Analysts at KeyCorp, Credit Suisse, and Deutsche Bank have lowered their price targets for MRVI, with KeyCorp downgrading the stock to Sector Weight.
MRVI has reported its second-quarter 2023 financial results, and the company has issued FY 2023 earnings guidance, with the stock hitting a new 52-week low at $10.76.

Newcomers· Aug 20

Maravai LifeSciences Holdings Inc (MRVI) stock has surged 25% in one day, with a key catalyst being the company's essential role in producing nucleic acids and mRNA building blocks for drug makers.
Newcomers are focusing on the stock's technical levels, with some analysts providing price targets and investment outlooks, while others are questioning whether MRVI is a buy, sell, or hold at current levels.
The company's recent price jump, extending a roughly 26% pop the day before, has some traders excited about potential future gains, with one analyst suggesting a possible 100% gain from current levels due to vaccine-related news.

Generated by AI

Maravai LifeSciences Holdings has seen its share price swing sharply in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$7.65 price supported by the cash flows the business can generate over time, based on a Discounted Cash Flow (DCF) view of its intrinsic value? The stock has delivered a 171.3% return over the past year, which puts real pressure on the question of whether that move is fully backed by the cash the business is...

5d agoYahoo Finance

Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In?

Maravai LifeSciences Holdings (MRVI) has been drawing attention after recent share price swings, with the stock closing at US$7.37 on 24 September 2026. Investors are weighing mixed return patterns across different holding periods. Recent trading in Maravai LifeSciences Holdings has been choppy, with a 7-day share price return of 7.75% but a 30-day move that is down 12.57%, while the 90-day gain of 20.42% and year to date share price return of 116.76% signal momentum that has cooled recently...

5d agoYahoo Finance

UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target

21d agoInvesting.com

UBS Adjusts Maravai Lifesciences Price Target to $8 From $2.50, Maintains Neutral Rating

Maravai Lifesciences Holdings (MRVI) has an average rating of overweight and mean price target of $5

21d agoYahoo Finance

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel (MRVI)

27d agoSeeking Alpha

Maravai Lifesciences stock reaches 52-week high of 8.15 USD

1mo agoInvesting.com

Also Discussed

Investors talking about MRVI also mention

#	Name	Attention
1	Theravance Biopharma Inc.TBPH	0%new
2	Kewaunee Scientific Corporation Common StockKEQU	0%0
3	Nature's Sunshine Products, Inc.NATR	0%new
4	Vera Therapeutics Inc.VERA	0%new
5	Ascendis Pharma A/SASND	0%new
6	ULY - Urgent.ly Inc. Common Stock	——
7	Olema Pharmaceuticals, Inc.OLMA	0%new
8	Legend Biotech Corporation ADRLEGN	0%+0
9	Virax Biolabs Group Ltd.VRAX	0%+0
10	Tenon Medical, Inc.TNON	0%new

Maravai LifeSciences Holdings, Inc. Class A Common Stock

Healthcare
Biotechnology

Maravai LifeSciences Holdings, Inc. Class A Common Stock represents ownership in Maravai LifeSciences Holdings, Inc., a life sciences company focused on products and services that support drug development, vaccine creation, cell and gene therapy research, and diagnostics. The company serves biopharmaceutical, biotechnology, and research customers through specialized offerings in nucleic acid production and biologics safety testing. Its product portfolio includes reagents, enzymes, nucleic acid tools, and analytical services used across molecular biology, genomics, and bioprocessing workflows. Maravai LifeSciences plays a role in the broader healthcare and life sciences market by supplying critical inputs that help enable laboratory research, therapeutic development, and quality testing across the drug development process. The company is headquartered in San Diego, California, and its business is organized around current operating segments that address research and production needs in advanced biologics and diagnostics.

Website

Location

10770 Wateridge Circle

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about MRVI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 20

Maravai LifeSciences Holdings, Inc. (MRVI) jumped 14% to $8.24, extending a 26% pop the day before, after Moderna-Merck news.
MRVI's product, nucleic acids and mRNA building blocks, are essential for drug makers to build therapies, making it a key player in the industry.
MRVI is also being considered as a potential sleeper in the space, with its CDXs possibly holding value.

Generated by AI

Sentiment

Of the messages about MRVI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	75% -21.41	87.79% +14.9
Bearish	—	—	25% +21.41	12.21% -14.9

Bullish· Feb 23

$MRVI is expected to reach $10-12 next week, with buying activity ahead of the next week's ramp up.
$MRVI is forming a base, setting up for a potential move, with some investors already taking positions at current levels.
$MRVI's recent earnings beat and revenue topping estimates are seen as a positive sign for the company's future, with some investors expecting the stock to reach $14+.

Bearish· Feb 25

$MRVI has experienced a significant decline in value, with some analysts downgrading it to "Sell" and others giving it a "Hold" rating with negative signals and a falling trend.
Maravai Lifesciences is under investigation for securities fraud, which has led to a 24% decline in the stock's value and a $13.74M "smart money" net outflow.
The company's poor performance has led to a loss of investor confidence, with many investors experiencing significant losses and some even averaging down their positions in anticipation of a future buyout.

Generated by AI

Topics

Of the messages about MRVI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	42.5%	63.05%
Technical Analysis	100%	100%	57.5%	10.25%
Analysts	0%	0%	0%	9.77%
Earnings	0%	0%	0%	8.82%
Macro	0%	0%	0%	8.1%
Controversies	0%	0%	0%	0%

Announcements· Sep 7

Maravai LifeSciences Holdings, Inc. ($MRVI) has launched a proposed secondary offering of Class A common stock by selling stockholders.
The company announced that Thompson Street Capital Partners has acquired Vector Laboratories, a protein detection business.
Maravai LifeSciences Holdings, Inc. has filed a Form S-1 registration statement with the SEC, indicating plans for a potential IPO.

Technical Analysis· Jul 23

A golden cross is forming on the daily chart, indicating a bullish structure, and traders are advised to trade pullbacks to the 50 SMA.
The price is forming higher lows, creating an ascending triangle pattern, and a measured breakout could aim toward the $8.00 region.
The price is testing horizontal resistance, and a breakout on above-average volume could confirm bulls and target the next swing high, but failure to breach with volume may lead to a short-term pullback to support.

Generated by AI

Community

Of the messages about MRVI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	27.63%	26.25%
Newcomers	100%	100%	72.37%	73.75%

Regulars· Aug 8

Maravai LifeSciences Holdings, Inc. (MRVI) is experiencing a significant decline in the pre-market, down -11.16%.
Analysts at KeyCorp, Credit Suisse, and Deutsche Bank have lowered their price targets for MRVI, with KeyCorp downgrading the stock to Sector Weight.
MRVI has reported its second-quarter 2023 financial results, and the company has issued FY 2023 earnings guidance, with the stock hitting a new 52-week low at $10.76.

Newcomers· Aug 20

Maravai LifeSciences Holdings Inc (MRVI) stock has surged 25% in one day, with a key catalyst being the company's essential role in producing nucleic acids and mRNA building blocks for drug makers.
Newcomers are focusing on the stock's technical levels, with some analysts providing price targets and investment outlooks, while others are questioning whether MRVI is a buy, sell, or hold at current levels.
The company's recent price jump, extending a roughly 26% pop the day before, has some traders excited about potential future gains, with one analyst suggesting a possible 100% gain from current levels due to vaccine-related news.

Generated by AI

Maravai LifeSciences Holdings

Social

Aug 20

Bullish· Feb 23

Bearish· Feb 25

Announcements· Sep 7

Technical Analysis· Jul 23

Regulars· Aug 8

Newcomers· Aug 20

Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers?

Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In?

UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target

UBS Adjusts Maravai Lifesciences Price Target to $8 From $2.50, Maintains Neutral Rating

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel (MRVI)

Maravai Lifesciences stock reaches 52-week high of 8.15 USD

Also Discussed

Maravai LifeSciences Holdings, Inc. Class A Common Stock

Company Information

Location

Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers?

Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In?

UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target

UBS Adjusts Maravai Lifesciences Price Target to $8 From $2.50, Maintains Neutral Rating

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel (MRVI)

Maravai Lifesciences stock reaches 52-week high of 8.15 USD

Also Discussed

Social

Aug 20

Bullish· Feb 23

Bearish· Feb 25

Announcements· Sep 7

Technical Analysis· Jul 23

Regulars· Aug 8

Newcomers· Aug 20